To assess the treatment outcome and overall efficacy of the novel technique of a transvaginal subfascial synthetic sling (TVSS) in comparison to the standard trans-obturator tape (TOT-O) mid-urethral sling for female stress urinary incontinence (SUI).
Artificial urinary sphincter (AUS) is the gold standard for the management of moderate to severe stress urinary incontinence (SUI) in the male population. While outcomes of this device in postprostatectomy incontinence (PPI) are widely described, those obtained for incontinence after benign prostatic obstruction (BPO) surgery remains poorly explored.
There is a relative lack of data regarding how patients weigh various factors when choosing a treatment strategy for interstitial cystitis/bladder pain syndrome (IC/BPS). Our aim is to describe patient experience with their current and prior treatments and discuss factors they consider when choosing a treatment.
We investigated the association between overactive bladder (OAB) and urinary metabolites in men. This prospective observational study included 42 men aged 65-80 years. The 3-day frequency volume chart (FVC), International Prostate Symptom Score (IPSS), and quality of life score were adapted to assess the micturition behavior.
Detrusor overactivity (DO) is a urodynamic observation characterized by fluctuations in detrusor pressure (Pdet) of the bladder. Although detecting DO is important for the management of bladder symptoms, the invasive nature of urodynamic studies (UDS) makes it a source of discomfort and morbidity for patients.
Increased time after spinal cord injury (SCI) is associated with a migration to bladder managements with higher morbidity such as indwelling catheter (IDC). Still it is unclear how this affects bladder-related quality of life (QoL).
To systematically summarize evidence on the costs related to chronic pelvic pain (CPP) for women. Electronic databases (MEDLINE, EMBASE, PubMed, and Cochrane Library) were searched from 1990 up until January 2021, and limited to only English and French studies.
In a subset analysis of data from a 6-month, multicenter, non-interventional study, we compared change in symptoms and quality of life (QoL), and treatment tolerability, in men with moderate to severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving tamsulosin (TAM, 0.
During the General Assembly 2021 the EAU members formally approved, with 94% of the General Assembly’s votes, the establishment of a new EAU Policy Office to make sure that the interests of European urologists and urological patients are taken into account on a European level. Prof. Hein Van Poppel is assigned as the Office’s first […]
The Let’s Talk Prostate Cancer Expert Group has released five Calls to Action for the 2019-2024 EU legislative period to address five key challenges in the treatment of people with advanced prostate cancer in Europe. The Expert Group, chaired by MEP Tiemo Wölken (DE, on the left in the photo next to Prof. Hein Van Poppel), […]
